The Predictive Role of Germinal Center or Non-Germinal Center Phenotypes in Diffuse Large B-Cell Lymphoma Patients Receiving CHOP or R-CHOP

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5290-5290
Author(s):  
Sun-ah Lee ◽  
Hun-Mo Ryoo ◽  
Sung Hwa Bae ◽  
Hyun Young Jung ◽  
Saet Byul Jang ◽  
...  

Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma. It can be divided into the germinal center (GC) and non-GC subtypes by immunohistochemistry based on the expression of CD10, Bcl-6 and MUM-1. The GC Subtype had a significantly better survival rate than the non-GC subtype. These subtypes are predictors of outcome in DLBCL patients receiving CHOP (cyclophosphamide, adriamycin, vincristine and prednisone). Recently a significant improvement of outcome has been obtained by combining a monoclonal anti-CD20 antibody, Rituximab, with chemotherapy. We conducted the retrospective study to evaluate the predictive role of GC or non-GC subtypes in DLBCL patients receiving CHOP or rituximab-CHOP (R-CHOP). We searched the DLBCL patients diagnosed at Daegu Catholic University Hospital between 2000 and 2007. Rituximab was introduced into the treatment since 2003. Both the immunohistochemical and clinical data could be analyzed in forty six patients. According to the expression of CD10, Bcl-6 and MUM-1, we divided DLBCLs into the GC or non-GC subgroups (Blood. 2004;103:275-282). The median follow-up duration was 22.5 months. 21 and 25 patients were received CHOP and R-CHOP, respectively. 12 and 34 patients were classified into the GC and non-GC subgroups. The GC subtype showed a better overall survival (OS) than the non-GC subtype (p=0.046), but not progression-free survival (PFS) (p=0.633). The GC subtype did not predict the outcome in CHOP and R-CHOP group, respectively. In R-CHOP group, the expression of Bcl-6 was associated with a better OS (p=0.033). The GC subtype showed a better OS in low IPI (IPI 0–2) with borderline significance (p=0.054), but not in high IPI group (IPI 3–5) (p=0.429). In conclusion, the GC subtype showed a better OS in whole patients group, but didn’t show the superior outcome than the non-GC subtype in CHOP subgroup or R-CHOP subgroup, respectively, in this study. It may be due to the small size of the GC subtype. The prospective, large scale study is recommended.

Blood ◽  
2016 ◽  
Vol 128 (2) ◽  
pp. 239-248 ◽  
Author(s):  
Julie Marie Matthews ◽  
Shruti Bhatt ◽  
Matthew P. Patricelli ◽  
Tyzoon K. Nomanbhoy ◽  
Xiaoyu Jiang ◽  
...  

Key Points GCK signaling is activated in DLBCL, and this signaling is important to DLBCL proliferation and survival. Therapeutic targeting of GCK is feasible and may advance efforts to cure DLBCL patients.


2010 ◽  
Vol 43 (1) ◽  
pp. 237-240 ◽  
Author(s):  
Suhail Al-Salam ◽  
Ahmad Shaaban ◽  
Maha Alketbi ◽  
Naveed U. Haq ◽  
Samra Abouchacra

Blood ◽  
2016 ◽  
Vol 127 (12) ◽  
pp. 1564-1574 ◽  
Author(s):  
Tibor Bedekovics ◽  
Sajjad Hussain ◽  
Andrew L. Feldman ◽  
Paul J. Galardy

Key Points The neuronal marker UCH-L1 is induced in, and specifically augments the oncogene-induced transformation of, GCB cells. High levels of UCHL1 identify patients with GC DLBCL with an increased risk for poor outcomes.


2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Ying Huang ◽  
Sheng Ye ◽  
Yabing Cao ◽  
Zhiming Li ◽  
Jiajia Huang ◽  
...  

Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), respectively. GCB patients had a better 5-year OS than non-GCB patients whether treated with CHOP or not (65.0% versus 40.9%;P=0.011). In contrast, there is no difference in the 5-year OS for the GCB and non-GCB with R-CHOP (76.5% versus 61.3%;P=0.141). In non-GCB subtype, additional rituximab improved survival better than CHOP (61.3% versus 40.9%;P=0.0303). These results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of IHC-defined GCB and non-GCB phenotypes in DLBCL by improving the prognostic value of non-GCB subtype of DLBCL.


Haematologica ◽  
2018 ◽  
Vol 104 (6) ◽  
pp. e256-e259 ◽  
Author(s):  
Luca Aresu ◽  
Serena Ferraresso ◽  
Laura Marconato ◽  
Luciano Cascione ◽  
Sara Napoli ◽  
...  

2010 ◽  
Vol 6 (1) ◽  
pp. 47-57 ◽  
Author(s):  
Celso Arrais Rodrigues ◽  
Poliana Alves Patah ◽  
Yana A. S. Novis ◽  
Chitra Hosing ◽  
Marcos de Lima

Sign in / Sign up

Export Citation Format

Share Document